AbbVie 2014 Annual Report Download - page 127

14FEB201503003896
17JAN201314185859
15MAR201411192791
13NOV201221352027
INFORMATION CONCERNING DIRECTOR NOMINEES
(ITEM 1)
The board of directors consists of three classes with each class currently comprised of three directors. Directors
of one class are elected each year for a term of three years. The Class III directors are presented for re-election to hold
office until the expiration of their term at the 2018 annual meeting of stockholders and until their successors are elected
and qualified or until their earlier death or resignation.
Directors are elected by stockholders if a majority of the votes cast are ‘‘for’’ a director’s re-election at the
Annual Meeting, excluding abstentions and broker non-votes. For more information on the director majority vote
standard, see AbbVie’s By-Laws as listed as an exhibit to AbbVie’s 2014 Annual Report on Form 10-K.
Class III—Directors Whose Terms Expire in 2015
................................................................................................................................................................................................................................................................................................................................................................................................
President, Austin Investment Advisors
Ms. Austin is president of Austin Investment Advisors, a private investment and consulting firm, a
position she has held since 2004. From July 2009 through July 2010, Ms. Austin also served as the
president and chief executive officer of Move Networks, Inc., a provider of Internet television
services. Ms. Austin previously served as president and chief operating officer of DIRECTV, Inc.
Ms. Austin also previously served as executive vice president and chief financial officer of Hughes
Electronics Corporation and as a partner of Deloitte & Touche LLP. Ms. Austin is also a director of
Audit Abbott Laboratories, Target Corporation, Teledyne Technologies, Inc. and Telefonaktiebolaget LM
Compensation Ericsson. Through her extensive management and operating roles, including her financial roles,
Ms. Austin contributes significant oversight and leadership experience, including financial expertise
and knowledge of financial statements, corporate finance and accounting matters.
Chairman of the Board and Chief Executive Officer, AbbVie Inc.
Mr. Gonzalez is the chairman and chief executive officer of AbbVie. He served as Abbott’s
executive vice president of the pharmaceutical products group from July 2010 to December 2012,
and was responsible for Abbott’s worldwide pharmaceutical business, including commercial
operations, research and development, and manufacturing. He also served as president, Abbott
Ventures Inc., Abbott’s medical technology investment arm, from 2009 to 2011. Mr. Gonzalez
joined Abbott in 1977 and held various management positions before briefly retiring in 2007,
including: Abbott’s president and chief operating officer; president, chief operating officer of
Abbott’s Medical Products Group; senior vice president and president of Abbott’s former Hospital
Products Division (now Hospira, Inc.); vice president and president of Abbott’s Health Systems
Division; and divisional vice president and general manager for Abbott’s Diagnostics Operations in
the United States and Canada. As a result of his service as Abbott’s executive vice president,
Pharmaceutical Products Group since July 2010, his previous service as Abbott’s president and
chief operating officer and his more than 30-year career at Abbott, Mr. Gonzalez has developed
valuable business, management and leadership experience, as well as extensive knowledge of
AbbVie and its global operations. Mr. Gonzalez’s experience and knowledge enable him to
contribute to AbbVie’s board key insights into strategic, management, and operational matters.
2015 Proxy Statement 7
Roxanne S. Austin
Committees:
Director since: 2013
Age: 54
Richard A. Gonzalez
Director since: 2013
Age: 61